Dulaglutide is a once-weekly injectable GLP-1 receptor agonist from Eli Lilly, marketed as Trulicity for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes. It is FDA- and EMA-approved and TGA-registered, supported by the AWARD trial program and the REWIND cardiovascular outcomes trial. It is a prescription medicine used under medical supervision.

Is Dulaglutide approved for medical use?

Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. United States (FDA): Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020. European Union (EMA): Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014). Australia (TGA): Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.

Is Dulaglutide legal in Australia?

Dulaglutide in Australia (TGA): Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.

Is Dulaglutide banned in sport?

Dulaglutide under the World Anti-Doping Agency (WADA) code: Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.

Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)

Dulaglutide

Approvedaka Trulicity, LY2189265

Dulaglutide is an approved once-weekly GLP-1 therapy for type 2 diabetes. It is a GLP-1 analogue fused to an antibody (IgG4 Fc) fragment, a design that extends its half-life. Randomized trials in the AWARD program show reductions in HbA1c and body weight, and the REWIND trial demonstrated a reduction in major adverse cardiovascular events in a broad type 2 diabetes population. It is not approved as a stand-alone weight-management medicine.

Compare

Mechanism

In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite. Technically, it is a GLP-1 receptor agonist consisting of GLP-1 analogue peptides covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment; the Fc fusion increases molecular size and slows clearance to allow once-weekly dosing. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake.

Regulatory Status by Region

United States (FDA)Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.
Australia (TGA)Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
European Union (EMA)Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).
WADANot prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.

See the full regulatory status matrix

Key Studies

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (Gerstein et al.) (opens in a new tab) (Lancet 2019;394:121-130; PMID 31189511)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6; Dungan et al.) (opens in a new tab) (Lancet 2014;384:1349-1357)

Related Clinical Trials

Latest research

Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA). (opens in a new tab)
Diabetologia · Aug 19, 2026
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. (opens in a new tab)
Diabetes, obesity & metabolism · Aug 17, 2026
Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. (opens in a new tab)
European journal of pharmacology · Aug 17, 2026
Dulaglutide. (opens in a new tab)
· Aug 15, 2026

See all recent Dulaglutide research

Common Questions

What is Dulaglutide?: Dulaglutide is a once-weekly injectable GLP-1 receptor agonist from Eli Lilly, marketed as Trulicity for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes. It is FDA- and EMA-approved and TGA-registered, supported by the AWARD trial program and the REWIND cardiovascular outcomes trial. It is a prescription medicine used under medical supervision.
Is Dulaglutide approved for medical use?: Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. United States (FDA): Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020. European Union (EMA): Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014). Australia (TGA): Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
How does Dulaglutide work?: In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite. Technically, it is a GLP-1 receptor agonist consisting of GLP-1 analogue peptides covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment; the Fc fusion increases molecular size and slows clearance to allow once-weekly dosing.
Is Dulaglutide legal in Australia?: Dulaglutide in Australia (TGA): Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
Is Dulaglutide banned in sport?: Dulaglutide under the World Anti-Doping Agency (WADA) code: Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.